ALKS: Alkermes plc

ALKS新闻

• 18:23 RHHBY Reports Positive Phase III Data on Breast Cancer Drug
• 17:16 JAZZ Hits 52-Week High on Encouraging Gastric Cancer Study Data
• 15:36 Avadel Board Labels Lundbeck Acquisition Bid a Superior Proposal
• 12:20 古根海姆上调Centessa制药股票目标价至43美元，看好试验数据
• 12:19 Guggenheim raises Centessa Pharmaceuticals stock price target to $43 on promising trial data
• 22:37 Alkermes plc (ALKS) Shareholder/Analyst Call - Slideshow (NASDAQ:ALKS) 2025-11-17
• 22:37 Alkermes plc (ALKS) Shareholder/Analyst Call Transcript
• 14:32 FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings
• 10:59 隆德贝克收购要约估值Avadel每股最高23美元
• 10:58 Lundbeck values Avadel at up to $23 per share in takeover bid
• 10:10 Truist Securities上调Alkermes股票目标价至55美元，基于积极试验数据
• 10:09 Truist Securities raises Alkermes stock price target to $55 on positive trial data
• 00:55 Merck Swoops In On Buyout Bonanza With A $9.2 Billion Cidara Therapeutics Deal
• 00:18 Avadel Surges 20% On Lundbeck's Surprise Alkermes-Topping Bid
• 16:04 美股异动 | 获两大药企争夺收购 Avadel Pharmaceuticals(AVDL.US)涨超20%
• 13:11 GILD's Investigational Regimen for HIV Treatment Meets Primary Goal
• 12:54 阿尔克姆斯回应伦德贝克对阿瓦德尔的潜在竞争性收购要约
• 12:53 Alkermes responds to potential rival bid for Avadel from Lundbeck
• 12:10 Avadel制药股价飙升，收到每股23美元收购要约
• 12:09 Avadel stock soars after receiving $23 per share acquisition offer
• 11:37 Lundbeck's Higher Buyout Proposal Challenges Alkermes' Pending $2 Billion Avadel Deal - Avadel Pharmaceuticals (NASDAQ:AVDL), Alkermes (NASDAQ:ALKS)
• 18:46 Cytokinetics Gains 11.4% in a Week: Is There More Room for Growth?
• 10:27 美银美林重申Alkermes股票"优于大盘"评级，基于嗜睡症药物数据
• 19:20 Avadel制药股价创52周新高至19.06美元